A Predictor of Early Cognitive Decline A Predictor of Early Cognitive Decline
A new study looks at the relationship between cerebral amyloidosis and cognitive decline in patients with autosomal dominant Alzheimer disease. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 16, 2015 Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news
Brain's Ability to Clear Amyloid Declines With AgeBrain's Ability to Clear Amyloid Declines With Age
The aging brain takes longer to clear amyloid-beta, a new study shows, which may explain why risk for the disease increases with age. It may also in the future allow risk prediction for Alzheimer's and amyloidosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 19, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Alnylam begins patisiran’s Apollo-Ole trial for ATTR amyloidosis
Alnylam Pharmaceuticals has started the Phase III open-label extension study (Apollo-Ole) with patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) to treat TTR-mediated amyloidosis (ATTR amyloidosis) in patients with familial… (Source: Drug Development Technology)
Source: Drug Development Technology - July 20, 2015 Category: Pharmaceuticals Source Type: news
Two-Step Tx Shows Promise in Systemic Amyloidosis (CME/CE)
(MedPage Today) -- Significant declines in liver stiffness with an anti-amyloid monoclonal antibody. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 15, 2015 Category: Gastroenterology Source Type: news
Molecular Heart Imaging Could Spot Cardiac AmyloidosisMolecular Heart Imaging Could Spot Cardiac Amyloidosis
Myocardial scintigraphy with the bone radiotracer technetium-99m hydroxymethylene diphosphonate has prognostic value for patients with transthyretin-type amyloidosis, new research suggests. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2015 Category: Consumer Health News Tags: Radiology News Source Type: news
Localized Amyloidosis Carries Low Risk of Progression to Systemic DiseaseLocalized Amyloidosis Carries Low Risk of Progression to Systemic Disease
The prognosis for patients with localized amyloidosis appears to be good for long-term survival, but patients still need to be assessed and monitored for the more dangerous systemic amyloidosis, UK researchers report. Reuters Health Information (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 26, 2015 Category: Primary Care Tags: Family Medicine/Primary Care News Source Type: news
Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards
The Brian D. Novis Research Awards honor the IMF's founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 3, 2015 is the deadline for applications. For more information and grant applications click HERE. (Source: International Myeloma Foundation)
Source: International Myeloma Foundation - April 23, 2015 Category: Hematology Source Type: news
Consumer Information on: Lixelle Beta 2-microglobulin Apheresis Column - H130001
The Lixelle Beta 2-microglobulin Apheresis Column (Lixelle Column) is a device that treats dialysis-related amyloidosis, a complication of kidney failure. The Lixelle Column contains specialized beads that remove a protein called Beta 2-microglobulin... (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - March 19, 2015 Category: Medical Equipment Source Type: news
FDA OKs First Device for Dialysis-Related AmyloidosisFDA OKs First Device for Dialysis-Related Amyloidosis
The authorization had a special humanitarian device exemption, used for a disease or condition that affects fewer than 4000 people in the United States each year. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 11, 2015 Category: Consumer Health News Tags: Nephrology News Alert Source Type: news
UCLA study shows feasibility of blood-based test for diagnosing Alzheimer’s Disease
UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer’s disease.
Although approximately 5 million Americans are living with Alzheimer’s, no reliable blood-based test currently exists for the neurodegenerative disorder that is the sixth-leading cause of death in the United States. Using blood-based biomarkers — a signature of proteins in the blood that indicate the presence of a disease — to diagnose Alzheimer’s could be a key advance.
“Blood-based biomarkers would have the impo...
Source: UCLA Newsroom: Health Sciences - March 11, 2015 Category: Universities & Medical Training Source Type: news
FDA Authorizes Use Of First Device To Treat Patients With Dialysis-Related Amyloidosis
The U.S. Food and Drug Administration recently authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Medical Design Online News)
Source: Medical Design Online News - March 10, 2015 Category: Medical Equipment Source Type: news
First Device Approved for Dialysis-Related Amyloidosis
Title: First Device Approved for Dialysis-Related AmyloidosisCategory: Health NewsCreated: 3/6/2015 12:00:00 AMLast Editorial Review: 3/9/2015 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - March 9, 2015 Category: Rheumatology Source Type: news
FDA authorizes use of first device to treat patients with dialysis-related amyloidosis
The U.S. Food and Drug Administration today authorized use of Lixelle Beta 2-microglobulin Apheresis Column, the first device to treat dialysis-related amyloidosis (DRA). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 6, 2015 Category: American Health Source Type: news
Amyloid formation may link Alzheimer disease and type 2 diabetes
The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D). However, little is known about whether different forms of amyloid proteins interact or how amyloid formation begins in vivo. A new study has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 17, 2015 Category: Science Source Type: news
Amyloid formation may link Alzheimer disease and type 2 diabetes
(Elsevier Health Sciences) The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease and type 2 diabetes. A study published in The American Journal of Pathology has found evidence that amyloid from the brain can stimulate the growth of fibrils in the murine pancreas and pancreatic-related amyloid can be found along with brain-related amyloid in human brain senile plaques. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 17, 2015 Category: Global & Universal Source Type: news
